SA
IOVA icon

Scarborough Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Scarborough Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$105 – 400
2026
Q1 		$105 Buy
+30
New +$96 ﹤0.01% 733
2024
Q1 		– Sell
-6
Closed -$49 – 541
2023
Q4 		$49 Buy
+6
New +$31 ﹤0.01% 710

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Scarborough Advisors's IOVA Position: Q2 2026 in Review

Scarborough Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 30 shares — an estimated $105 sold.

Scarborough Advisors first reported a position in IOVA in Q4 2023 and held it in 2 quarters. The position peaked at $105 in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Scarborough Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 30 Iovance Biotherapeutics shares in Q2 2026, an estimated $105.
  • Scarborough Advisors first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Scarborough Advisors's Iovance Biotherapeutics position peaked at $105 in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.